Panic Disorder and Cardiac Risk
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The reason for increased cardiac mortality in panic disorder has not been precisely identified, but possibly is due to chronic activation of the cardiac stimulant (sympathetic) nerves, which may predispose the individual with panic disorder to disorders of cardiac rhythm and coronary artery spasm. The uniqueness of this study lies in its comprehensive evaluation of a psychobiological approach to the treatment of panic disorder using change in biological, behavioural and psychological variables as criteria for efficacy. 50 patients aged between 18 and 60 years will be recruited; both males and females. They will be treated with either cognitive behavioural therapy (CBT) or SSRI (selective serotonin re-uptake inhibitor) antidepressants or a combination of both.
This project will firstly compare individuals with panic disorder who demonstrate abnormal brain transmitter (noradrenaline, serotonin) with those who demonstrate normal activity of these neurotransmitters, on interoceptive accuracy for changes in sympathetic nervous system arousal. It is predicted that individuals who demonstrate abnormal activity of these neurotransmitters will also demonstrate enhanced interoceptive ability to detect changes in arousal levels. Secondly, this project will evaluate the effects of a psychobiological treatment approach to panic disorder involving a combination of CBT and SSRI. This approach will be compared to the effects of both these interventions alone on a comprehensive array of measures related to panic disorder. It is predicted that the combined approach will be the most effective intervention on behavioural, psychological and biological variables, and cardiac risk. We will also be able to assess whether changes in panic disorder severity are associated with changes in interoceptive accuracy.
| Condition | Intervention |
|---|---|
|
Panic Disorder |
Drug: SSRI Drug: CBT Drug: CBT/SSRI |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Panic Disorder and Cardiac Risk: Evaluation of a Psychological Treatment Which Addresses Biology, Psychology and Behaviour |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Panic disorder
Exclusion Criteria:
- Comorbid heart disease
- Comorbid significant psychiatric illness
- Significant suicide risk
- HIV/AIDS hepatitis B/c
Contacts and Locations| Contact: David A Barton, MBBSFRANZCP | 61393428946 | david.barton@bigpond.com |
| Contact: Murray Esler, PhD | 61385321338 | Murray.Esler@baker.edu.au |
| Australia, Victoria | |
| Baker Heart Research Institute | Recruiting |
| Melbourne, Victoria, Australia, 3121 | |
| Contact: David A Barton, MBBS 61393428946 david.barton@bigpond.com | |
| Sub-Investigator: David A Barton, MBBS | |
| Principal Investigator: | Murray A Esler, MBBS Phd | Baker Heart Research Insitute |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00168506 History of Changes |
| Other Study ID Numbers: | NHMRC P - 01 |
| Study First Received: | September 10, 2005 |
| Last Updated: | April 4, 2007 |
| Health Authority: | Australia: National Health and Medical Research Council |
Keywords provided by Baker Heart Research Institute:
|
panic disorder cardiac risk |
Additional relevant MeSH terms:
|
Panic Disorder Anxiety Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 19, 2013